CN113660951A - 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂 - Google Patents

含有抗il-6受体抗体的抑制bbb功能低下的抑制剂 Download PDF

Info

Publication number
CN113660951A
CN113660951A CN202080025917.0A CN202080025917A CN113660951A CN 113660951 A CN113660951 A CN 113660951A CN 202080025917 A CN202080025917 A CN 202080025917A CN 113660951 A CN113660951 A CN 113660951A
Authority
CN
China
Prior art keywords
seq
sequence
brain barrier
blood brain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080025917.0A
Other languages
English (en)
Chinese (zh)
Inventor
竹下幸男
神田隆
芹泽贤一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN113660951A publication Critical patent/CN113660951A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080025917.0A 2019-03-29 2020-02-17 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂 Pending CN113660951A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-068693 2019-03-29
JP2019068693 2019-03-29
PCT/JP2020/005965 WO2020202839A1 (ja) 2019-03-29 2020-02-17 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤

Publications (1)

Publication Number Publication Date
CN113660951A true CN113660951A (zh) 2021-11-16

Family

ID=72667972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080025917.0A Pending CN113660951A (zh) 2019-03-29 2020-02-17 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂

Country Status (12)

Country Link
US (1) US20220220210A1 (https=)
EP (1) EP3949989A4 (https=)
JP (2) JPWO2020202839A1 (https=)
KR (1) KR20210144795A (https=)
CN (1) CN113660951A (https=)
AU (1) AU2020255449A1 (https=)
BR (1) BR112021017702A2 (https=)
CA (1) CA3133610A1 (https=)
IL (1) IL286716A (https=)
MX (1) MX2021011464A (https=)
TW (1) TWI859192B (https=)
WO (1) WO2020202839A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
EP4413998A4 (en) * 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
KR20240145472A (ko) * 2022-01-19 2024-10-07 추가이 세이야쿠 가부시키가이샤 사트랄리주맙을 사용하는 자기면역 뇌염의 치료

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110098450A1 (en) * 2008-09-26 2011-04-28 Chugai Seiyaku Kabushiki Kaisha Antibody Molecules
CN102119174A (zh) * 2008-07-17 2011-07-06 诺瓦提斯公司 使用治疗性抗体的组合物和方法
CN104168956A (zh) * 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
WO2016027859A1 (ja) * 2014-08-20 2016-02-25 中外製薬株式会社 蛋白質溶液の粘度測定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
KR101680906B1 (ko) * 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
JP4809930B2 (ja) 2009-03-19 2011-11-09 中外製薬株式会社 関節リウマチ治療剤
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US11447752B2 (en) 2016-04-15 2022-09-20 Yamaguchi University In vitro model for blood-brain barrier and method for producing in vitro model for blood-brain barrier

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119174A (zh) * 2008-07-17 2011-07-06 诺瓦提斯公司 使用治疗性抗体的组合物和方法
US20110098450A1 (en) * 2008-09-26 2011-04-28 Chugai Seiyaku Kabushiki Kaisha Antibody Molecules
CN104168956A (zh) * 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
WO2016027859A1 (ja) * 2014-08-20 2016-02-25 中外製薬株式会社 蛋白質溶液の粘度測定方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MANABU ARAKI等: ""Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica"", 《NEUROLOGY》, vol. 38, no. 15, pages 26 - 30 *
YASUNOBU ARIMA等: ""Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier"", 《CELL》, vol. 148, no. 3, pages 2 *
张静茹等: ""视神经脊髓炎与血脑屏障"", 《中华脑科疾病与康复杂志》, vol. 6, no. 03, pages 177 - 180 *
钱雪琴等: ""神经系统白塞病的诊治"", 《医学综述》, vol. 23, no. 19, 31 October 2017 (2017-10-31), pages 3840 *

Also Published As

Publication number Publication date
TW202102540A (zh) 2021-01-16
TWI859192B (zh) 2024-10-21
WO2020202839A1 (ja) 2020-10-08
EP3949989A4 (en) 2022-12-14
JP2024102154A (ja) 2024-07-30
AU2020255449A1 (en) 2021-10-07
JPWO2020202839A1 (https=) 2020-10-08
BR112021017702A2 (pt) 2021-11-16
CA3133610A1 (en) 2020-10-08
MX2021011464A (es) 2021-10-22
IL286716A (en) 2021-12-01
EP3949989A1 (en) 2022-02-09
US20220220210A1 (en) 2022-07-14
KR20210144795A (ko) 2021-11-30

Similar Documents

Publication Publication Date Title
CN113660951A (zh) 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂
JP6245986B2 (ja) 治療におけるｃｄ８９活性化
KR20230097209A (ko) Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
KR20240063162A (ko) 혈액 응고 제 viii 인자 및/또는 활성화 혈액 응고 제 viii 인자의 활성의 저하 내지 결손에 의해 발증 및/또는 진전되는 질환의 예방 및/또는 치료에 이용되는 의약 조성물
Kwekkeboom et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
US10556953B2 (en) Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
HK40056582A (en) Anti il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
US20230355815A1 (en) Active delivery of radiotracers across the blood brain barrier
AU2020267329B2 (en) Treatment of brain ischemia-reperfusion injury
KR20210016332A (ko) 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
CA3138857C (en) Treatment of brain ischemia-reperfusion injury
CN120248122B (zh) 一种靶向uPAR的单链抗体、嵌合抗原受体及其应用
CN118662628A (zh) 抗ox40抗体在治疗炎症或免疫性疾病中的应用
HK40099176A (zh) 抗cd38抗体及其用途
HK40065388A (en) Treatment of brain ischemia-reperfusion injury
JP2024538064A (ja) ミクログリア活性化を抑制するための方法
HK40116467A (zh) 抗ox40抗体在治疗炎症或免疫性疾病中的应用
CN114980901A (zh) 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
Verstege et al. Inhibition of soluble TNF-α by single domain camel antibodies does not prevent experimental colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056582

Country of ref document: HK